MiMedx outlines $250M-$260M 2026 net sales as it targets >20% adjusted EBITDA margin with Sanara (NASDAQ:MDXG)

seekingalpha.com · 2026-10-29

MiMedx Q3 2026: surgical growth, EBITDA rebound, lowered sales guidance, and FTC deal delay.

TickrTrends take: MiMedx projects 2026 net sales in the range of $250M to $260M and aims for adjusted EBITDA margins exceeding 20%, which would represent significant profitability improvement from current levels. Given TickrTrends' current assessment that MDXG is overvalued, investors monitoring valuation metrics should track whether the company achieves these margin targets and whether revenue growth reaches the guidance range, as execution gaps could pressure the stock further. The Healthcare sector context matters here, as investors will need to evaluate whether these projections justify the current valuation or whether they suggest the overvaluation signal is appropriate.

Read the full story at seekingalpha.com →